clinical trials

ICER weighing issuing advice on trial design
ICER weighing issuing advice on trial design
BioCentury
ICER
clinical trials
trial design
Flag link:
Public seems to know value of clinical trials, but not how they work
Public seems to know value of clinical trials, but not how they work
Reuters
clinical trials
Flag link:
Bristol-Myers Squibb's Opdivo Misses Primary Endpoint in Ph III Study in Small Cell Lung Cancer
Bristol-Myers Squibb's Opdivo Misses Primary Endpoint in Ph III Study in Small Cell Lung Cancer
CP Wire
Bristol-Myers Squibb
Opdivo
Small-Cell Lung Cancer
clinical trials
Flag link:
Bristol-Myers to invest in Compugen, collaborate in clinical trials
Bristol-Myers to invest in Compugen, collaborate in clinical trials
Yahoo/Reuters
Bristol-Myers Squibb
CompuGen
clinical trials
solid tumors
COM701
Opdivo
Flag link:
The Importance of Diversity in Clinical Trials (Because Right Now, It's Lacking)
The Importance of Diversity in Clinical Trials (Because Right Now, It's Lacking)
BioSpace
clinical trials
diversity
Flag link:
UK clinical trials fall as Brexit clouds drug approval process
UK clinical trials fall as Brexit clouds drug approval process
Reuters
UK
Brexit
clinical trials
Flag link:
Peninsula biotech coughs up 40 percent of its value on failed clinical trial
Peninsula biotech coughs up 40 percent of its value on failed clinical trial
Bizjournals.com
clinical trials
IPOs
Menlo Therapeutics
serlopitant
Flag link:
A double date with destiny for Alkermes
A double date with destiny for Alkermes
EP Vantage
Alkermes
FDA
clinical trials
ALKS 5461
ALKS 3831
Flag link:
Xencor’s lead drug fails a PhII test for lupus, shares slide
Xencor’s lead drug fails a PhII test for lupus, shares slide
Endpoints
Xeoncor
lupus
XmAb5871
clinical trials
Flag link:
UK alarm bells are ringing as a biotech cuts a few trial sites, fretting over Brexit’s impact on drug development
UK alarm bells are ringing as a biotech cuts a few trial sites, fretting over Brexit’s impact on drug development
Endpoints
Brexit
UK
clinical trials
Recardio
Flag link:
Bausch Health announces good Phase III results from psoriasis therapy
Bausch Health announces good Phase III results from psoriasis therapy
GoinPharma
Bausch Health
psoriasis
clinical trials
Bryhali
Flag link:
Clinical Trials: FDA Releases Two Draft Guidances
Clinical Trials: FDA Releases Two Draft Guidances
RAPS.org
FDA
clinical trials
Flag link:
Are Clinical Trials Really That Costly? These Researchers Say They Don’t Have to Be
Are Clinical Trials Really That Costly? These Researchers Say They Don’t Have to Be
Xtalks
clinical trials
Flag link:
Aldeyra plans reproxalap phase 3 after wrapping up dry eye disease trial
Aldeyra plans reproxalap phase 3 after wrapping up dry eye disease trial
Fierce Biotech
Aldeyra Therapeutics
dry eye disease
clinical trials
reproxalap
Flag link:
Reata’s bardoxolone hits goals in phase 2 kidney disease trial
Reata’s bardoxolone hits goals in phase 2 kidney disease trial
Fierce Biotech
Reata
kidney disease
Bardoxolone
clinical trials
Flag link:
J&J's Esketamine Fails to Meet Endpoint in Phase III Study
J&J's Esketamine Fails to Meet Endpoint in Phase III Study
Yahoo/Zacks.com
JNJ
clinical trials
esketamine
treatment-resistant depression
Flag link:
Phase 3 Trial Costs Estimated at $19M, Study Finds
Phase 3 Trial Costs Estimated at $19M, Study Finds
RAPS.org
clinical trials
Flag link:
Alexion’s Soliris wows in rare disease PhIII trial, opening up a new franchise worth $500M-$700M
Alexion’s Soliris wows in rare disease PhIII trial, opening up a new franchise worth $500M-$700M
Endpoints
Alexion
Soliris
clinical trials
NMOSD
Flag link:
Farxiga Meets One Primary Endpoint in Large Ph III Cardiovascular Outcomes Trial in 17,000 Patients with Type 2 Diabetes
Farxiga Meets One Primary Endpoint in Large Ph III Cardiovascular Outcomes Trial in 17,000 Patients with Type 2 Diabetes
CP Wire
AstraZeneca
Farxiga
Dapagliflozin
clinical trials
type 2 diabetes
cardiovascular disease
Flag link:
FDA lifts clinical hold on Sarepta's Duchenne MD gene therapy, clearing the way to a quick launch of a pivotal trial
FDA lifts clinical hold on Sarepta's Duchenne MD gene therapy, clearing the way to a quick launch of a pivotal trial
Endpoints
Sarepta Therapeutics
FDA
gene therapy
Duchenne Muscular Dystrophy
clinical trials
Flag link:

Pages